METHODS OF REDUCING DOSES OF ERYTHROPOIETIN STIMULATING AGENTS IN HYPORESPONSIVE PATIENTS

The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA require...

Full description

Saved in:
Bibliographic Details
Main Authors LIN, Vivian H, PRATT, Raymond, GUPTA, Ajay, GUSS, Carrie
Format Patent
LanguageEnglish
French
German
Published 10.10.2018
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.
Bibliography:Application Number: EP20140802543